Dermatophytic onychomycosis is a fungal infection of nail caused...

Dermatophytic onychomycosis is a fungal infection of nail caused by dermatophytes. It makes the nails look white and opaque, thickened, and brittle. People in the age group of 60- 65 years with diabetes or disease of the small blood vessels (peripheral vascular disease) are at increased risk. Dermatophytic onychomycosis therapeutics market consists of drugs used for a treatment of the disease. The global dermatophytic onychomycosis therapeutics market was valued at US$ 2,870 Mn in 2014. North America was the largest market for dermatophytic onychomycosis therapeutics, accounting for over 43% revenue share of the overall market in 2014, followed by Europe with around 28% share. North America market is expected to exhibit the highest CAGR of 9.2% during the forecast period (2015–2021), followed by Europe. Factors such as increasing per capita healthcare spending, rising aging population, consumers’ disposition towards maintaining aesthetic appearing nails, and growing product innovation are expected to support the growth of the dermatophytic onychomycosis therapeutics market during the forecast period. The global dermatophytic onychomycosis therapeutics market is projected to be valued at US$ 3,057.8 Mn by the end of 2015 and is further expected to reach US$ 4,706.3 Mn by the end of 2021, at a CAGR of 7.5%. By product, the nail paint segment accounted for about 70% share of overall market value in 2014. By treatment, the oral segment was valued at US$ 861 Mn in 2014 and is expected to increase at a CAGR of 5.2% during the forecast period to account for US$ 1,221.9 Mn by 2021. By distribution channels, the drug store segment contributed the highest revenue of US$ 1,343.2 Mn, accounting for approximately 47% market share in 2014. Independent pharmacies were the second-largest segment by distribution channel, accounting for about 20% revenue share in 2014. Key players of the global dermatophytic onychomycosis therapeutics market include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc.